This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Worth separating two things that post #29 runs together.
Adding the boring version of CJC-1295, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do not say which, and the difference is not cosmetic.
It is worth checking rather than assuming, which costs nothing.
Following, with nothing to contribute beyond having asked the same thing elsewhere.
Picking up post #34: that is the part I would want checked first.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
A purity figure without a method for a short peptide is nearly uninterpretable, because short peptides can be run on gradients that resolve almost nothing and still produce a clean-looking trace.
Second-hand, so weight it accordingly.
The useful distinction on CJC-1295 is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Taking post #38 at face value and following it one step further.
CJC-1295 exists in two forms in circulation — with and without the drug affinity complex — and they have very different half-lives. Product descriptions frequently do not say which, and the difference is not cosmetic.
The strength of my opinion here exceeds the strength of my evidence.
CJC-1295: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
That matches what I have seen, for whatever a single anecdote is worth.
Whatever the answer on CJC-1295 turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the correction.
Post #50 is the version of this I will quote in future. One addition.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
A weak preference rather than a position.
Second-hand on CJC-1295, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
Confirming post #55 from a second method, which matters more than confirming it from a second person.
CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist. Supplier labelling frequently does not distinguish them clearly, so confirming which you have is important.
That is where I would start, not where I would stop.
Post #55 describes the usual case. This is about the unusual one.
Reframing CJC-1295 slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
Something worth flagging about CJC-1295: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.